News

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Meet with us at the 2019 J.P. Morgan Healthcare Conference

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Meet with us at the 2019 J.P. Morgan Healthcare Conference

The Sentien team will be attending the 2019 J.P. Morgan Healthcare Conference. This event continues to be one of the life science industry’s largest conferences of the year. Contact us today to schedule a time to meet with our team and learn more about our business.
SCHEDULE A MEETING >

Sentien Biotechnologies Appoints Dr. Pedro Huertas as Chief Medical Officer

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies Appoints Dr. Pedro Huertas as Chief Medical Officer

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel cell therapies to restore balance to the immune system, today announced the appointment of Pedro Huertas, M.D. Ph.D., as its Chief Medical Officer.  Dr. Huertas will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101. Read More >

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress

Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
SEE VIDEO >

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial

In September, our clinical trial was selected by Cell Trials Data as its Featured Advanced Cell Therapy Trial.
READ MORE >

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.
READ MORE >

Sentien to sponsor and exhibit at the Cellular Therapeutics in Trauma & Critical Care Conference from May 17-19 in San Francisco

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien to sponsor and exhibit at the Cellular Therapeutics in Trauma & Critical Care Conference from May 17-19 in San Francisco

Sentien Biotechnologies is a sponsor and exhibitor at the 2017 Cellular Therapeutics & Critical Care Conference being held from May 17-19 in San Francisco. This is the third in a series of conferences, entitled “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Medicine: Looking towards the Future.”

Load More